Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jushi HoldingsJUSHF +9.18%51 EV-to-EBIT is 69.54 as of Jul. 31, 2026, which is 1178% above its 10-year median of 5.44. GuruFocus rates JUSHF with a GF Score™ of 51/100 and a GF Value™ of $0.50 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 692 Drug Manufacturers companies, Jushi Holdings ranks worse than 91.33% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Jushi Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $362.5 Mil.
Jushi Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jushi Holdings EV-to-EBIT Related Terms
Jushi Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Jushi Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jushi Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jushi Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jushi Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Jushi Holdings's EV-to-EBIT falls into.
Jushi Holdings's current Enterprise Value is $344.9 Mil.
Jushi Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jushi Holdings (JUSHF) has a EV-to-EBIT of 69.54 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jushi Holdings and its competitors. This is 1178% above median its historical median of 5.44. According to the industry distribution chart, Jushi Holdings ranks #632 out of 692 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Jushi Holdings' EV-to-EBIT too high?
Jushi Holdings' current EV-to-EBIT of 69.54 is 1178% above median its 10-year median of 5.44. The Drug Manufacturers industry median EV-to-EBIT is 15.60. Jushi Holdings' value of 69.54 is 345.8% above this industry median. Based on the distribution chart, Jushi Holdings ranks #632 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jushi Holdings has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jushi Holdings' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jushi Holdings ranks #632 out of 692 companies for EV-to-EBIT. This places Jushi Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.60. Jushi Holdings' value of 69.54 is 345.8% above this benchmark. While the company's 10-year median is 5.44 vs. the industry median of 15.60, Jushi Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.60, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jushi Holdings's current EV-to-EBIT of 69.54 is 345.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jushi Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jushi Holdings's current EV-to-EBIT is 69.54, which is 1178% above median its own 10-year median of 5.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jushi Holdings stock overvalued right now?
Based on GuruFocus' analysis, Jushi Holdings (JUSHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.50, compared to a current price of $0.42 — trading 17% below its estimated fair value. The current EV-to-EBIT is 69.54, which is 1178% above median its 10-year median of 5.44 and 345.8% above the Drug Manufacturers industry median of 15.60. Jushi Holdings' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Jushi Holdings (JUSHF), the current EV-to-EBIT is 69.54 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jushi Holdings (JUSHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jushi Holdings stock appears to be undervalued.
The current stock price of $0.42 is trading 17% below its estimated GF Value™ of $0.50.
GuruFocus considers Jushi Holdings to be Modestly Undervalued.
Key valuation signals for JUSHF:
EV-to-EBIT: 69.54 (1178% above median its 10-year median of 5.44)
GF Value™: $0.50 vs. price of $0.42 (17% below fair value)
Industry Position: 345.8% above the Drug Manufacturers median (#632 of 692)
No single metric tells the full story. See the JUSHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jushi Holdings Inc is a vertically integrated multi-state cannabis and hemp operator engaged in retail, distribution, cultivation, and processing in both medical and adult-use markets. The company operates a diverse portfolio of branded cannabis and hemp-derived assets built upon opportunistic acquisitions, distressed deals, and competitive applications. Its products are offered through brands like Hijinks, The Bank, The Lab, Seche, and Tasteology, among others. The company distributes its products through various retail dispensaries, including Nature's Remedy, Beyond Hello, and NuLeaf, and also operates an e-commerce platform called The Jushi Shop, offering branded apparel, accessories, and other products of its different brands. All of its revenues are generated within the United States.
51GF Score
Get the complete analysis for JUSHF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JUSHF has been successfully added to your 
